TransCode Therapeutics, Inc.

NasdaqCM:RNAZ Stock Report

Market Cap: US$6.8m

TransCode Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:RNAZ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Mar 25BuyUS$55,685Thomas TracyIndividual1,250US$45.36

Insider Trading Volume

Insider Buying: RNAZ insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RNAZ?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,2580.151%
Institutions23,1332.78%
Hedge Funds52,2186.26%
General Public757,01090.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 11533%.

Top Shareholders

Top 22 shareholders own 9.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.26%
Anson Group
52,218US$426.1k1,190%0.09%
1.13%
UBS Asset Management AG
9,426US$76.9k2,950%no data
0.98%
Sabby Management, LLC
8,180US$66.7k0%0.27%
0.21%
Warberg Asset Management LLC
1,785US$14.6k0%0.07%
0.17%
Corsair Capital Management, L.P.
1,428US$11.7k0%no data
0.15%
Thomas Tracy
1,250US$10.2k0%no data
0.093%
Commonwealth Equity Services, LLC
774US$6.3k0%no data
0.077%
Private Capital Management, LLC
643US$5.2k0%no data
0.061%
Ground Swell Capital, LLC
512US$4.2k0%0.01%
0.021%
Morgan Stanley, Investment Banking and Brokerage Investments
178US$1.5k1,680%no data
0.016%
Geode Capital Management, LLC
131US$1.1k0%no data
0.0065%
Tower Research Capital Europe Limited
54US$440.863.6%no data
0.0016%
SBI Holdings Inc., Asset Management Arm
13US$106.10%no data
0.00096%
RBC Dominion Securities Inc., Asset Management Arm
8US$65.30%no data
0.0006%
Robert Dudley
5US$40.80%no data
0.00036%
Osaic Wealth, Inc. , Asset Management Arm
3US$24.50%no data
0.00024%
Thomas Fitzgerald
2US$16.30%no data
0.00012%
BlackRock, Inc.
1US$8.20%no data
0.00012%
Philippe Calais
1US$8.20%no data
0.00012%
Strategic Advisers LLC
1US$8.20%no data
0.00012%
Bank of America Corporation, Asset Management Arm
1US$8.20%no data
0.00012%
The Lind Partners, LLC
1US$8.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 11:27
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TransCode Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.